Functions and indications of lorlatinib

Lorlatinib is a third-generation ALKtyrosine kinase inhibitor (TKI), mainly used for treatment pan>ALKpositive non-small cell lung cancer (NSCLC) and some ROS1positive patients. It was originally designed to overcome the problem of treatment failure due to drug resistance of first- and second-generation ALK inhibitors (such as crizotinib and alectinib), while showing significant efficacy in patients with central nervous system (CNS) metastasis.

Lorlatinib blocks cancer cell signaling pathways by selectively inhibiting the tyrosine kinase activities of ALK and ROS1, thereby inhibiting tumor growth and metastasis. What is unique about it is that it still has a strong inhibitory effect on multiple mutations of the ALK gene (including the G1202R mutation), and can penetrate the blood-brain barrier to effectively control and alleviate brain metastases. In addition, lorlatinib also shows good tolerance and is an important option in later-line treatment.

Treat diseases

1.ALKpositive non-small cell lung cancer: It is suitable for advanced patients who have failed other ALK inhibitor treatments, or the control effect on patients with brain metastases is more significant.

2.ROS1positive lung cancer: It also shows potential efficacy for some ROS1 rearranged NSCLC patients.

In multiple clinical studies, lorlatinib has demonstrated excellent objective response rate (ORR) and central nervous system response rate. For patients who have previously received two or more ALK inhibitors, the disease control rate can still reach 70%Above. In addition, for patients with brain metastases, the intracranial response rate exceeded 60%.

Larlatinib is an indispensable targeted drug for ALKpositiveNSCLC patients, especially for patients with drug resistance or brain metastasis. Patients need to use it under the guidance of a doctor to obtain maximum therapeutic benefits.

xa0

Reference materials:

1.Pfizer official website:https://www.pfizer.com

2.UpToDate - Lorlatinib overview:

https://www.uptodate.com/contents/lorlatinib-for-alk-positive-non-small-cell-lung-cancer